Tirzepatide shows no significant MACE reduction versus GLP-1 RAs in overweight or obese adults
Background
The treatment of obesity with glucagon-like peptide-1 (GLP-1) receptor agonists has demonstrated improvements in cardiovascular outcomes. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, is known to achieve greater weight loss than GLP-1 RAs alone. However, the comparative real-world cardiovascular outcomes of tirzepatide versus existing GLP-1 RAs in adults with overweight or obesity have remained uncertain, representing a critical knowledge gap for clinical decision-making.
Study Design
Researchers conducted a systematic review and meta-analysis, searching PubMed/MEDLINE, Embase, and Cochrane Central through March 2026. They included eight studies (one randomized controlled trial and seven observational studies) that compared tirzepatide with GLP-1 receptor agonists and reported cardiovascular outcomes. Data were extracted on study characteristics and outcomes, primarily using adjusted hazard ratios (HRs) where available. The risk of bias was rigorously assessed using RoB 2 for randomized trials and ROBINS-I for observational studies, ensuring a comprehensive evaluation of study quality.
Results
The analysis, encompassing 323,439 patients, revealed that tirzepatide was not associated with a statistically significant reduction in major adverse cardiovascular events (MACE) when compared to GLP-1 receptor agonists. The pooled hazard ratio for MACE was 0.85 (95% CI 0.70-1.04), with substantial heterogeneity observed across studies (I2 = 90.4%). Effect estimates were directionally consistent, though not statistically significant, for secondary outcomes: all-cause mortality (HR 0.90, 95% CI 0.79-1.02) and cardiovascular mortality (HR 0.88, 95% CI 0.76-1.00).
Key Findings
- Tirzepatide did not significantly reduce MACE compared to GLP-1 RAs (HR 0.85, 95% CI 0.70-1.04).
- High heterogeneity was observed across studies for MACE outcomes (I2 = 90.4%).
- All-cause mortality (HR 0.90, 95% CI 0.79-1.02) and cardiovascular mortality (HR 0.88, 95% CI 0.76-1.00) showed directionally consistent but non-significant reductions.
- In patients with type 2 diabetes, lower risks were estimated for all-cause mortality (HR 0.85, 95% CI 0.76-0.94) and heart failure (HR 0.75, 95% CI 0.58-0.97).
Why It Matters
This meta-analysis suggests that while tirzepatide is highly effective for weight loss, its comparative cardiovascular benefit over existing GLP-1 receptor agonists is not yet statistically established. For individuals using or considering tirzepatide, this means that current evidence does not support a superior MACE reduction compared to other GLP-1 RAs. Do not assume a differential cardiovascular protective effect between tirzepatide and GLP-1 RAs based on current data. Clinically, this highlights the ongoing need for large-scale, long-term randomized controlled trials to definitively clarify the comparative cardiovascular effects of tirzepatide, especially given the predominance of observational data and high heterogeneity in this review. Until then, choices between these agents for cardiovascular risk reduction should be made cautiously.
tirzepatide
glp-1-ra
obesity
cardiovascular-outcomes
meta-analysis
type-2-diabetes